Systemic Treatment Options in Hepatocellular Carcinoma

Hepatocellular Carcinoma in Sheep

Treatment options after sorafenib failure in patients with hepatocellular carcinoma

Second line therapy after failure of sorafenib continues to be under study. Prognosis of hepatocellular carcinoma is measured in months, with median overall survival reaching 10.7 months with sorafenib. Because of the modest net benefit sorafenib has contributed, and rising incidence of hepatocellular carcinoma in the world, continued efforts are ongoing to look for efficient upfront, second li...

Preclinical studies of 166Ho-chitosan for treatment of hepatocellular carcinoma

Introduction: Recently, due to the special characteristics of 166Ho and chitosan, 166Ho-chitosan complex was developed for treatment of tumors such as hepatocellular carcinoma. This complex has been lately prepared with high radiochemical purity in our lab. The preclinical studies of the complex however should be performed to evaluate the tracer concentration in target and...

Hepatocellular carcinoma in a sheep

At necropsy of a five-year-old sheep, a pear shaped, lobular yellow-brownish mass measuring about 12 ×15 × 20 cm was found to involve the right hepatic lobe. Microscopic examination revealed two trabecularand solid patterns of neoplastic hepatocytes. In solid pattern, there were numerous tumoral giant cells thatcontain one or more large hyperchromatic bizarre-shaped nuclei scattered among clust...

Systemic treatment of hepatocellular carcinoma: Past, present and future

Hepatocellular carcinoma (HCC) is a common neoplasia which represents the second leading cause of cancer related death. Most cases occur in developing countries, but its incidence is rising in Western countries due to hepatitis C. Although hepatitis therapies have evolved and the HCC screening has increased in several areas, 40% present with advanced disease which is only amenable for palliativ...